These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22186026)

  • 21. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease.
    Sanchez-Martin P; Lahuerta M; Viana R; Knecht E; Sanz P
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118613. PubMed ID: 31758957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
    Rai A; Mishra R; Ganesh S
    Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice.
    Machado-Salas J; Avila-Costa MR; Guevara P; Guevara J; Durón RM; Bai D; Tanaka M; Yamakawa K; Delgado-Escueta AV
    Exp Neurol; 2012 Jul; 236(1):131-40. PubMed ID: 22542948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased oxidative stress and impaired antioxidant response in Lafora disease.
    Romá-Mateo C; Aguado C; García-Giménez JL; Ibáñez-Cabellos JS; Seco-Cervera M; Pallardó FV; Knecht E; Sanz P
    Mol Neurobiol; 2015; 51(3):932-46. PubMed ID: 24838580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.
    Sinha P; Verma B; Ganesh S
    Mol Neurobiol; 2021 Mar; 58(3):1088-1101. PubMed ID: 33094475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein degradation and quality control in cells from laforin and malin knockout mice.
    Garyali P; Segvich DM; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2014 Jul; 289(30):20606-14. PubMed ID: 24914213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lafora disease: from genotype to phenotype.
    Parihar R; Rai A; Ganesh S
    J Genet; 2018 Jul; 97(3):611-624. PubMed ID: 30027899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin.
    Rao SN; Maity R; Sharma J; Dey P; Shankar SK; Satishchandra P; Jana NR
    Hum Mol Genet; 2010 Dec; 19(23):4726-34. PubMed ID: 20858601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.
    Sullivan MA; Nitschke S; Steup M; Minassian BA; Nitschke F
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
    Romá-Mateo C; Aguado C; García-Giménez JL; Knecht E; Sanz P; Pallardó FV
    Free Radic Biol Med; 2015 Nov; 88(Pt A):30-41. PubMed ID: 25680286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
    Berthier A; Payá M; García-Cabrero AM; Ballester MI; Heredia M; Serratosa JM; Sánchez MP; Sanz P
    Mol Neurobiol; 2016 Mar; 53(2):1296-1309. PubMed ID: 25627694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lafora Disease: A Ubiquitination-Related Pathology.
    García-Gimeno MA; Knecht E; Sanz P
    Cells; 2018 Jul; 7(8):. PubMed ID: 30050012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
    Ganesh S; Delgado-Escueta AV; Sakamoto T; Avila MR; Machado-Salas J; Hoshii Y; Akagi T; Gomi H; Suzuki T; Amano K; Agarwala KL; Hasegawa Y; Bai DS; Ishihara T; Hashikawa T; Itohara S; Cornford EM; Niki H; Yamakawa K
    Hum Mol Genet; 2002 May; 11(11):1251-62. PubMed ID: 12019206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sánchez MP
    Epilepsia; 2017 Mar; 58(3):467-475. PubMed ID: 28098937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epm2a
    Burgos DF; Sciaccaluga M; Worby CA; Zafra-Puerta L; Iglesias-Cabeza N; Sánchez-Martín G; Prontera P; Costa C; Serratosa JM; Sánchez MP
    Neurobiol Dis; 2023 Jun; 181():106119. PubMed ID: 37059210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased oxidative stress and impaired antioxidant response in Lafora disease.
    Romá-Mateo C; Aguado C; García-Giménez JL; Ibáñez-Cabellos JS; Seco-Cervera M; Pallardó FV; Knecht E; Sanz P
    Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S47. PubMed ID: 26461389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
    Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
    Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.